Dublin, Ireland — Alkermes plc has appointed biopharmaceutical executive Anne C. Whitaker as an independent member of its Board of Directors.
Whitaker brings commercial and operational experience from senior leadership roles across pharmaceutical and biotechnology companies, as well as experience serving on public and private company boards.
“Anne joins our Board at a defining time for Alkermes,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “We are building on our strong commercial performance and advancing a differentiated pipeline that we believe has the potential to address significant unmet needs in neuroscience. Anne’s experience and perspectives will be valuable assets as we execute on our strategy and work to develop new medicines for patients and create long-term value for our shareholders. I look forward to working with Anne as we build on the momentum we have established across the business.”
Richard Pops, Chairman of the Board of Alkermes, said Whitaker’s experience leading companies of different sizes and stages, along with her board service, would bring additional perspective to the company.
“Anne’s experience as an executive and CEO across organizations of varying sizes and stages, together with her extensive service on public and private company boards, gives her a unique perspective on the key decisions that drive long-term success in our industry,” Pops said. “We are very pleased to welcome Anne to the Alkermes Board as we continue to advance our strategic priorities.”
“I am honored to join Alkermes’ Board at such an exciting time in the company’s evolution,” Whitaker said. “Alkermes has built a strong foundation through scientific innovation, disciplined execution and value creation. I look forward to working alongside the Board and management team in support of Alkermes’ commitment to improving outcomes for patients through innovative medicines.”
Whitaker most recently served as Chief Executive Officer of Aerami Therapeutics, a clinical-stage biopharmaceutical company. She previously served as Chief Executive Officer of Novoclem Therapeutics Inc. and Synta Pharmaceuticals Corporation and held senior commercial and executive positions at Bausch Health Companies Inc., Sanofi S.A. and GlaxoSmithKline.
She currently serves on the boards of publicly traded companies Basilea Pharmaceutica Ltd. and ICON plc, as well as private companies QurAlis LLC, Bespak Inc., Beaconcure Technologies and Trinity Partners LLC.
Whitaker previously served on the boards of Nykode Therapeutics, OraSure Technologies Inc., Ergomed plc and Faron Pharmaceuticals, among other life sciences companies.
She holds a B.S. in chemistry with a minor in business administration from the University of North Alabama.
